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The National Center for Research Re-sources has funded a new program 
to support preclinical and clinical gene 
therapy efforts. The National Gene Vec-
tor Biorepository (NGVB) will bring a 
variety of programs online during the 
next year. One of the resources will be a 
continuation of the Pharmacology/Toxi-
cology (Pharm/Tox) Database formerly 
maintained by the National Gene Vector 
Laboratory. The purpose of the database is 
to provide gene therapy investigators with 
a catalog of gene therapy biodistribution 
and toxicology studies on file with the US 
Food and Drug Administration (FDA).
Pharm/tox refers to any in vitro or 
animal study that seeks to determine the 
therapeutic or toxic effect of a drug prod-
uct (including gene therapy). Pharm/tox 
studies are designed to estimate the dose 
and dosing schedule as well as to identify 
the potential toxicity of drug products 
before they are administered to humans. 
These studies, which are required by the 
FDA, are submitted in an Investigational 
New Drug (IND) application—the es-
tablished mechanism for FDA oversight 
of investigational drug development. The 
IND application must outline what is 
known about the drug, how the drug will 
be manufactured, the clinical protocol un-
der which the drug will be administered, 
and how the patients will be informed 
about potential risks; in addition, it must 
include the results of pharm/tox studies.
The type and scope of a pharm/tox 
study will depend on several factors, 
including the product itself, the route of 
administration, the disease being treated, 
and the availability of suitable animal 
models. Given the complexity of prod-
ucts and disease indications, a custom-
ized pharm/tox plan is usually required. 
Therefore, investigators are well advised 
to draft a detailed pharm/tox plan, then 
engage the FDA via a Pre-Pre-IND or 
Pre-IND meeting before initiating the 
study, to minimize the chance that the 
study will be inadequate or insufficient to 
support the IND application.
Why is the Pharm/Tox Database need-
ed? There are at least three reasons to pro-
vide a public catalog of pharm/tox studies. 
First, the results of such studies are gener-
ally not available. Many go unpublished 
because they are not viewed as hypothesis-
driven research, and studies that support 
clinical trials generally have no significant 
findings. The second need for the database 
is financial. These studies, especially when 
done in nonhuman primates, are expen-
sive and use valuable animal resources. 
Because the costs of the studies can exceed 
the cost of vector production and testing, 
there is a financial incentive for academic 
investigators and the National Institutes of 
Health (NIH) to avoid unnecessary dupli-
cation of studies. Third, the time needed 
to admit new products into clinical trial 
may be shortened if duplicative pharm/
tox studies are avoided.
How can the database decrease costs? 
To protect the proprietary information 
of commercial sponsors, the FDA is pro-
hibited by law from disclosing or using 
pharm/tox data submitted by one invest-
igator for the benefit of another. An ex-
ception can be made when the FDA is 
given permission by the individual who 
submitted the original data. This is done 
with a “letter of cross-reference” writ-
ten by the owner of the pharm/tox data. 
The letter authorizes the FDA to utilize 
the data in its deliberation of a specified 
IND application. By allowing the FDA to 
consider studies it has on file, it is hoped 
that subsequent gene therapy IND appli-
cations will not be viewed in isolation but 
can build on existing pharm/tox data and 
provide more focused (and less expen-
sive) studies.
Generally, an individual who obtains a 
letter of cross-reference from a commer-
cial or academic institution is not shown 
the primary data contained in the refer-
enced file. Because it is ultimately the FDA 
that decides whether existing data can be 
used in support of an IND application, not 
sharing the primary data protects con-
fidentiality and proprietary information 
while still accomplishing the goal of per-
mitting the FDA to reference the data. The 
NGVB Pharm/Tox database was designed 
with similar considerations; primary data 
are not contained in the database, but de-
tailed information is provided to investi-
gators so that they can identify studies of 
relevance to their IND application.
What is contained in the database? It 
contains information regarding the study 
design and methodology, dose level, as-
sessment vector type and manufacturing 
grade, species used in animal studies, 
route of administration, and detailed lists 
of analyses performed. For each study 
there are details on the number of ani-
mals evaluated and the dosing, as well as 
summary information about the results 
and implications of the study. The site 
and sponsor of the study are also listed.
Who should use the database? Inves-
tigators who have not previously submit-
ted a pharm/tox study to the FDA will 
find the database an excellent educa-
tional resource. The studies can serve as 
examples and help identify the scope of 
work required for previous studies that 
had similar routes of administration, vec-
tor systems, and/or transgenes. A tutorial 
is being developed to provide additional 
guidance on study design and interacting 
with the FDA.
The database should be reviewed by 
anyone submitting an IND application 
to determine whether prior work can be 
used to decrease the scope (and cost) of 
the pharm/tox studies. For example, a 
review of the database may identify an 
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Table 1 Current and pending studies listed in the National Gene Vector Biorepository Pharmacology/Toxicology Database
Study Institution Indication Animal (no.) Delivery route
1 Safety and Germline Transmission of rAAV2-hAAT 
Vector After IM Injection in the Baboon
University of Florida α1-Antitrypsin 
deficiency
Baboon (Papio spp.) (10) i.m.
2 Single Dose 6-Month Toxicity Study of Adeno-Associated 
Virus–Cystic Fibrosis (AAV-CFTR) Gene Vector in the 
Rhesus Monkey
University of Florida Cystic fibrosis Rhesus (16) i.b.
3 Toxicity and Biodistribution Study of rAAV-1-CB-hAAT 
in New Zealand White Rabbits
University of Florida α1-Antitrypsin 
deficiency
New Zealand white rabbit (24) i.m.
4 Toxicology and Biodistribution Study of rAAV-AAT 
Vectors in Rabbit Tissues
University of Florida α1-Antitrypsin 
deficiency
New Zealand white rabbit (31) i.m.
5 Effect of HCV Infection in Safety and Efficacy of Liver 
Delivery of rAAV-AAT
University of Florida Hepatitis C Chimpanzee (6) Portal vein
6 Single Dose Biodistribution Study of AAV-CB-AAT 
Comparing IM and IV Routes of Vector Administration 
in the C57/B16 Mouse
University of Florida α1-Antitrypsin 
deficiency
Mouse (36) i.m. and i.v.
7 Toxicology and Biodistribution Study of AAV-Mediated 
Gene Therapy for Muscular Dystrophy
University of Florida Muscular dystrophy Mouse C57BL/6-α-SG (130) i.m.
8 60-Day Subcutaneous Toxicity Study of Recombinant 
Adenovirus Expressing PDGF-B in C57B1/6 Mice.
University of Pennsylvania Venous leg ulcer Mouse (144) s.q.
9 Single Dose Subcutaneous Biodistribution Study of 
Recombinant Adenovirus Expressing PDGF-B in 
C57B1/6 Mice.
University of Pennsylvania Venous leg ulcer Mouse (32) s.q.
10 Single-Dose 3-Month Toxicity Study of Adeno-Associated 
Virus ATT Gene Vector in the C57/BL6 Mouse
University of Florida α1-Antitrypsin 
deficiency
Mouse (48) i.m.
11 Toxicity and Vector Distribution Study in Rats Following 
a Single Injection into the Submandibular Duct (test 
article Adenovirus/AdCMVH3)
NIDR/NIH Diabetes Wistar rat (120)
12 A 12-Week Toxicity Study of DNA Vaccine (pTVG-HP) 
Encoding Human Prostatic Acid Phosphatase (PAP) 
Administered Intradermally to Male Lewis Rats
University of Wisconsin–
Madison
Prostate cancer Lewis rat (75) i.d.
13 28-Day Prechronic Toxicity Biodistribution and 
Transgene Expression Study in Fischer 344 Rats for Single 
Submandibular Gland Injections of an Adenoviral Vector 
Carrying the Human Growth Hormone Gene (Ad-hGH)
NIDR/NIH Diabetes Fischer rat (144)
14 Evaluation of Potential Toxicity of Electroporation 
Mediated Delivery of a Plasmid Encoding for IL-12 in a 
Mouse Melanoma Model
H. Lee Moffit Center, 
Florida
Cancer; melanoma Mouse (250) s.q.
15 Dose Response of H5.001RSVTK in C57BL/6 Female 
Mice after Intraperitoneal Inoculation, With Ganciclovir 
on Days 2 to 15 Delivered Intraperitoneally (Ovarian 
Cancer Project)
University of Alabama Ovarian cancer Mouse (88) i.p.
16 Toxicological Safety Evaluation of DNA Plasmid 
Vaccines Against HIV-1, Ebola, Severe Acute Respiratory 
Syndrome, or West Nile Virus Is Similar Despite Differing 
Plasmid Backbones or Gene-Inserts
VRC/NIAID/NIH Multiple HIV/Ebola/
ARDS/WNV
Rabbit (100) i.m.
17 Biodistribution of DNA Plasmid Vaccines Against HIV-1, 
Ebola, Severe Acute Respiratory Syndrome, or West Nile 
Virus Is Similar, Without Integration, Despite Differing 
Plasmid Backbones or Gene Inserts
VRC/NIAID/NIH HIV Rabbit and mouse (163) i.m.
18 Myocarditis Following Adeno-Associated Viral Gene 
Expression of Human Soluble TNF Receptor (TNFRII.Fc) 
in Baboon Hearts
University of Pittsburgh Congestive heart 
failure
Baboon (Papio anubis) (6) Direct heart
19 A Single-Dose 90 Day Biodistribution Study of Viral 
Test Article HSV-NP2 Administered Subcutaneously in 
BALB/C Mice
University of Pittsburgh; 
Diamyd
Cancer pain Mouse (96) s.q.
20 A Single-Dose Toxicology Study of HSV-NP2 
Administered Subcutaneously in BALB/C Mice with 90 
Day Follow-up
University of Pittsburgh; 
Diamyd
Cancer pain Mouse (320) s.q.
21 Canine Biodistribution Study AAV6-CMV-SERCA2a University of Pittsburgh Congestive heart 
failure
Dog (28) Cardiac
22 Adenylyl Cyclase VI Gene Transfer for Congestive Heart 
Failure hAd5.hACVI
University of California, 
San Diego
Congestive heart 
failure
Yorkshire–Landrace farm pig, 
(Sus scrofa) (48)
Intracoronary
Table 1 continued on next page
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Table 1 Current and pending studies listed in the National Gene Vector Biorepository Pharmacology/Toxicology Database (continued)
Study Institution Indication Animal (no.) Delivery route
23 Final Biodistribution Report for One-Week 
Biodistribution Study of rAAV-RPE65 Following a 
Single Subretinal Injection in Cynomolgus Monkeys-
0406SU20.0 AAV2
University of Florida Retinal degeneration Cynomolgus monkey (6) Subretinal
24 Biodistribution Report for Three Month Biodistribution 
Study of rAAV-RPE65 Following a Single Subretinal 
Injection or Intravitreal Injection in Cynomolgus 
Monkeys 
University of Florida Retinal degeneration Cynomolgus monkey (11) Subretinal or 
intravitreal
25 Biodistribution of Adenovirus Type 5 and Type 35 Vector 
Vaccines Against Human Immunodeficiency Virus-1 
(HIV-1), Ebola, or Marburg Are Similar Despite Differing 
Adenovirus Serotype Vector, Manufacturer’s Construct, 
or Gene Inserts
VRC/NIAID/NIH HIV-1; multiple Rabbit (52) i.m.
26 Toxicological Safety of Adenovirus Type 5 and Type 35 
Vector Vaccines Against Human Immunodeficiency 
Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite 
Differing Adenovirus Serotype Vector, Manufacturer’s 
Construct, or Gene Inserts 
VRC/NIAID/NIH HIV-1; multiple Rabbit (181) i.m.
27 Biodistribution of rAAV-1 in Primate Tissue University of Florida α1-Antitrypsin 
deficiency
Rhesus macaque (6) i.p.
P Phase I/II Trial of Intrathoracic Delivery of Recombinant 
rAAV1-CBd300 GAA to the Diaphragm in Pompe 
Disease
University of Florida Pompe disease Mouse (150) i.m.
P Preclinical Study of AAV Mediated Gene Therapy for 
Pompe Disease by Direct Injection Into the Diaphragm of 
New Zealand White Rabbit
University of Florida Pompe disease Rabbit (Oryctolagus cuniculus) 
(12)
Diaphragm
P Toxicology and Biodistribution Study of rAAV-1-CB-
hAAT: Summary and Findings
University of Florida α1-Antitrypsin 
deficiency
Mouse (172) i.m. and i.v.
P Canine Toxicology Study AAV6-CMV-SERCA 2a University of Pittsburgh Congestive heart 
failure
Dog (28) Direct heart
P Direct Comparison Analysis of rAAV1 and rAAV5 
Pseudotyped Vectors Using Aerosol Delivery of Firefly 
and Renilla Luciferase Reporters Co-delivered to the 
Lungs of Chimpanzees
University of Florida Cystic fibrosis Chimpanzee (8) Bronchial 
aerosol
P Toxicology and Biodistribution Study of NUREL C3 in 
BALB/c Mice
University of Pittsburg Brain tumors Mouse (420) Intracranial
i.b., intrabronchial; i.d., intradermal; i.m., intramuscular; i.p., intraperitoneal; i.v., intravenous; NIAID, National Institute of Allergy and Infectious Diseases; NIDR, National 
Institute of Dental Research; NIH, National Institutes of Health; P, pending studies; s.q., subcutaneous; VRC, Vaccine Research Center.
existing study using a different trans-
gene but a similar vector, manufacturing 
method ology, and route of administra-
tion. Although the FDA may require a 
toxicological assessment of the trans-
gene, it might allow a limited biodis-
tribution study based on information 
already on file in another IND applica-
tion. The NGVB can facilitate the letter 
of cross-reference, and it is the expecta-
tion of NIH that letters will be provided 
to academic investigators for studies sup-
ported with NIH funds. For commercial 
entities that participate in this resource, 
the decision about whether to share this 
information is at their discretion.
The database can also serve as a 
resource for grant reviewers and NIH 
program officers to determine whether 
grant applicants are seeking funds for 
duplicative work.
A list of current and pending studies 
recorded in the database is provided in 
Table 1. The database search site can be 
viewed at http://www.ngvl.org/include/
tox/index.php, where short abstracts of 
the studies can be accessed. Access to the 
full contents of the database can be ob-
tained by registering with the NGVB Co-
ordinating Center. Academic, commercial, 
or other interested parties are welcome to 
register and view the database.
The NGVB also requests that anyone 
involved with important gene therapy 
pharm/tox studies contribute to the da-
tabase. The Coordinating Center can as-
sist in uploading the information and will 
make the process as easy as possible. Con-
tact information is provided on the NGVB 
website, https://www.ngvbcc.org.
Finally, over the next year the 
NGVB will be developing a variety of 
other support resources for gene ther-
apy investigators, including a reagents 
repository, assistance with vector in-
sertion site assays and analysis, and 
archiving services for FDA-monitored 
samples and products.
